Sansure Biotech Inc.
Symbol: 688289.SS
SHH
20.62
CNYDzisiejsza cena rynkowa
31.0215
Wskaźnik P/E
0.0048
Wskaźnik PEG
11.83B
Kapitalizacja MRK
- 0.03%
Rentowność DIV
Sansure Biotech Inc. (688289-SS) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4781.8 | 5663.8 | 4682.7 | |||||||
balance-sheet.row.short-term-investments | 0 | 548.3 | 2451.2 | 2046.5 | |||||||
balance-sheet.row.net-receivables | 0 | 732.8 | 1472.7 | 894.1 | |||||||
balance-sheet.row.inventory | 0 | 376.6 | 355.3 | 369.5 | |||||||
balance-sheet.row.other-current-assets | 0 | 58.4 | 33.6 | 20 | |||||||
balance-sheet.row.total-current-assets | 0 | 5949.6 | 7525.4 | 5966.2 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1055.2 | 785.3 | 481 | |||||||
balance-sheet.row.goodwill | 0 | 7.7 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 328 | 84.4 | 45.6 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 335.6 | 84.4 | 45.6 | |||||||
balance-sheet.row.long-term-investments | 0 | 974.3 | -1793.8 | -1533.2 | |||||||
balance-sheet.row.tax-assets | 0 | 73.8 | 69.6 | 25 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 65.6 | 2502.8 | 2105.8 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 2504.6 | 1648.3 | 1124.1 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.account-payables | 0 | 468.7 | 791.4 | 258.7 | |||||||
balance-sheet.row.short-term-debt | 0 | 77.2 | 14.3 | 8.5 | |||||||
balance-sheet.row.tax-payables | 0 | 17.7 | 216.4 | 101.3 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 18.2 | 13.6 | 6.4 | |||||||
Deferred Revenue Non Current | 0 | 32.5 | 30.5 | 25.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 340.5 | 712.9 | 2.4 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 77.7 | 89.3 | 45.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 18.2 | 13.6 | 6.4 | |||||||
balance-sheet.row.total-liab | 0 | 996.8 | 1661 | 709 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 588.5 | 588.5 | 400 | |||||||
balance-sheet.row.retained-earnings | 0 | 4882.7 | 5077.1 | 3820 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 395.2 | 377.4 | 294 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1334.9 | 1457.7 | 1854.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 7201.3 | 7500.6 | 6368.9 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.minority-interest | 0 | 223.6 | 12.2 | 12.4 | |||||||
balance-sheet.row.total-equity | 0 | 7424.9 | 7512.8 | 6381.3 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 1522.6 | 657.4 | 513.2 | |||||||
balance-sheet.row.total-debt | 0 | 95.4 | 27.9 | 14.9 | |||||||
balance-sheet.row.net-debt | 0 | -4138 | -3184.7 | -2621.3 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1936.7 | 2242.5 | 2616.6 | ||||||
cash-flows.row.depreciation-and-amortization | 0 | 89.1 | 53.9 | 26.7 | ||||||
cash-flows.row.deferred-income-tax | 0 | -40 | -8.1 | -4.6 | ||||||
cash-flows.row.stock-based-compensation | 0 | 60.8 | 5.6 | 4.6 | ||||||
cash-flows.row.change-in-working-capital | 0 | 203.3 | -402.1 | -50.4 | ||||||
cash-flows.row.account-receivables | 0 | -496.5 | -304.1 | -419.4 | ||||||
cash-flows.row.inventory | 0 | -282.1 | -93 | -212.1 | ||||||
cash-flows.row.account-payables | 0 | 496.5 | 3.1 | 585.7 | ||||||
cash-flows.row.other-working-capital | 0 | 485.4 | -8.1 | -4.6 | ||||||
cash-flows.row.other-non-cash-items | 0 | 308.9 | -14.8 | 49.4 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.acquisitions-net | 0 | -11.6 | 15.9 | 115 | ||||||
cash-flows.row.purchases-of-investments | 0 | -12140.6 | -7880 | -3725 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 11591.1 | 7125.6 | 2111.3 | ||||||
cash-flows.row.other-investing-activites | 0 | -46.9 | -0.9 | -108.7 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1166.7 | -1112.2 | -1716 | ||||||
cash-flows.row.debt-repayment | 0 | -17.2 | -55 | -55 | ||||||
cash-flows.row.common-stock-issued | 0 | 274.6 | 200 | 0 | ||||||
cash-flows.row.common-stock-repurchased | 0 | -257.4 | -200 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | -656.9 | -439.9 | -301.3 | ||||||
cash-flows.row.other-financing-activites | 0 | -259 | -193.7 | 1966.2 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -915.9 | -688.6 | 1609.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -10 | -34.3 | -44.6 | ||||||
cash-flows.row.net-change-in-cash | 0 | 466.2 | 42 | 2491.6 | ||||||
cash-flows.row.cash-at-end-of-period | 0 | 3099.1 | 2632.8 | 2590.8 | ||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2632.8 | 2590.8 | 99.2 | ||||||
cash-flows.row.operating-cash-flow | 0 | 2558.9 | 1877.1 | 2642.3 | ||||||
cash-flows.row.capital-expenditure | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.free-cash-flow | 0 | 2000.1 | 1504.2 | 2533.6 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1002.5 | 6450.4 | 4514.5 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 381.8 | 2655.4 | 1279 | |||||||
income-statement-row.row.gross-profit | 0 | 620.7 | 3795 | 3235.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.operating-expenses | 0 | 638.7 | 1262.2 | 666.9 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 1020.5 | 3917.5 | 1945.9 | |||||||
income-statement-row.row.interest-income | 0 | 54.7 | 48.4 | 32.5 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 136.8 | 290.8 | -20.7 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | -18 | 2339.8 | 2621.8 | |||||||
income-statement-row.row.income-before-tax | 0 | 432.6 | 2315.9 | 2616.2 | |||||||
income-statement-row.row.income-tax-expense | 0 | 62.3 | 379.2 | 373.7 | |||||||
income-statement-row.row.net-income | 0 | 363.7 | 1936.8 | 2242.7 |
Często zadawane pytania
Ile wynosi Sansure Biotech Inc. (688289.SS) aktywów ogółem?
Sansure Biotech Inc. (688289.SS) całkowite aktywa to 8454204974.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to N/A.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.729.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -0.496.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.321.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.334.
Co to jest Sansure Biotech Inc. (688289.SS) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 363721131.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 95444005.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 638676546.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 0.000.